Alexandria Real Estate Equities, Inc. an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. With our founding in 1994, Alexandria pioneered the life science real estate niche. Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative Mega campus ecosystems in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of December 31, 2025, Alexandria has a total market capitalization of 20.75 billion US dollars and an asset base in North America that includes 35.9 million RSF of operating properties and 3.5 million RSF of Class A/A+ properties undergoing construction. Alexandria has a long-standing and proven track record of developing Class A/A+ properties clustered in highly dynamic and collaborative Mega campus environments that enhance our tenant ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value. Alexandria Real Estate Equities, Inc. was incorporated in 1996 in Maryland, USA.
Valuation Insights | With price targets ranging from $79 to $130, ARE's specialized portfolio and potential biotech sector recovery offer compelling investment considerations |
Financial Outlook | Analysts project mixed results with a potential 9.8% Core FFO decrease in 2026, but highlight ARE's strong 7.14% dividend yield and growth prospects |
Market Headwinds | Explore ARE's response to challenges like oversupply and slower leasing, including portfolio optimization and strategic asset realignment |
Life Science Pionee | Alexandria Real Estate Equities leads in life science properties, with a strategic focus on Megacampuses and high-quality tenants in key innovation clusters |
Metrics to compare | ARE | Sector Sector - Average of metrics from a broad group of related Real Estate sector companies | Relationship RelationshipAREPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5.5x | 93.2x | 9.1x | |
PEG Ratio | 0.01 | −6.56 | 0.01 | |
Price / Book | 0.5x | 2.9x | 0.9x | |
Price / LTM Sales | 2.6x | 11.4x | 3.9x | |
Upside (Analyst Target) | 28.9% | 6.2% | 16.0% | |
Fair Value Upside | Unlock | −23.5% | 0.6% | Unlock |